Digest Network Come funziona
Network
/
Società
Re
Non verificato

Recursion Pharmaceuticals, Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaManagement/Organizzazione AziendaleMedicina Salute Benessere

4 comunicati stampa

Guarda tutti i comunicati
08/12/2025
Biotecnologia
Medicina Salute Benessere
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
Fonte
Recursion Pharmaceuticals, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
Press Release cover image
20/11/2024
Biotecnologia
Annunci Economici
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Fonte
Recursion Pharmaceuticals, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
22/10/2024
Biotecnologia
Medicina Salute Benessere
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
Fonte
Recursion Pharmaceuticals, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
02/10/2024
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Fonte
Recursion Pharmaceuticals, Inc.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0